Historical perspective on the role of amyloid fibres in disease

22
Amyloid diseases are a group of protein misfolding disorders defined by the 23 formation and deposition of insoluble protein fibres with a cross-fold [1,2]. Although 24 well known for their association with neurodegenerative disorders, such as 25
Alzheimer's and Parkinson's diseases, amyloid fibre formation is involved in a range 26 of human conditions, in which misfolded protein aggregates deposit in a localised or 27 systemic fashion [3] . Despite the increasing incidence of amyloidoses in our ageing 28 population, these disorders are remarkably difficult to prevent or ameliorate, since 29 the myriad of misfolded species that can form during amyloid assembly has 30 precluded the precise identification of the originators of toxicity. In addition, many 31 amyloid diseases are exacerbated by ageing due to the reduced efficiency of the 32 proteostasis machinery. This leads to increased protein misfolding and aggregation 33 events that accelerate the decline in protein homeostasis and enhance susceptibility 34 to amyloid toxicity [4, 5] . 35 Since their discovery, the pathological role of amyloid fibres has undergone a shifting 36 view; from the original findings implicating fibres as the causative agent of disease 37
[6], to current opinions, which describe fibres as inert end-stage products of 38 aggregation. Several reasons are responsible for this shift in opinion: i) amyloid 39 fibres, including those composed of amyloid beta (A)1-40/42, -synuclein, and islet 40 amyloid polypeptide (IAPP), have been shown to display limited toxicity in 41 comparison with oligomeric intermediates of their assembly [7] , ii) the conserved 42 cross-fold of the amyloid fibre core has emerged as an important functional motif in 43 a range of organisms, including prokaryotes, eukaryotes, and even humans [8, 9] , 44 and iii) amyloid fibres are highly stable thermodynamically, and are amongst the 45 strongest and stiffest of any known proteinaceous material [10] . Prion fibres, which 46 are structurally homologous to amyloid fibres, are the exception to this current view,and are firmly established as key facilitators of the spreading and infectivity observed 48 in prionopathies [11] . Notably, recent discoveries have also shown that disease-49 associated amyloid fibres, including fibres formed from A and -synuclein, facilitate 50 the spreading of amyloid formation in vivo [12] [13] [14] . 51
Interest in amyloid fibres as disease-relevant agents has undergone a renaissance in 52 recent years. Here, we examine evidence that places amyloid fibres as a key player 53 in the persistence, progression and propagation of amyloid disease through an array 54 of biological activities relevant to the long incubatory periods over which these 55 disorders manifest. Thus, an understanding of amyloid fibre structure, dynamics, and 56 biology may help to unravel the complexities of amyloid disease, and pave the way 57 towards developing successful therapies against these disorders. 58
Biological membranes and fibre-induced toxicity
59
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Concluding remarks
257
Here, we have summarized compelling evidence illustrating that amyloid fibres 258
should not be considered as inert products of aggregation, but rather as important 259 facilitators of the cellular degeneration and propagation of aggregation observed in 260 amyloid disease. Thus, the idea that oligomers are the primary progenitor of amyloid 261 disease needs to be revisited, and indeed all potential misfolded species, including 262 monomers, oligomers and fibres themselves, should be recognised as potential 263 contributors to amyloid disease. 264
The study of amyloid fibre structure, dynamics, and biology has helped to illuminate 265 the complex nature of amyloid diseases. Many key questions remain, including how 266 do unique fibre 'strains' cause different biological effects by modulating fibre stability 267 and dynamics, as well as the fibre 'interactome' (Outstanding Questions)? A better 268 understanding of the degenerative effects that unique fibre morphologies can elicit 269 will not only strengthen our understanding of the fundamental biology of amyloid 270 disease, but further our goal of therapeutic intervention in this devastating group of 271 protein-misfolding diseases. 272
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 How do amyloid fibres infect and spread between cells? Fibres are known to be able to access the cytosol when added extracellularly, but the mechanism by which this occurs remains poorly understood.
